Studies

Question 1

RTOG 0522

Answer 1

Phase III Randomized trial
Cisplatin + RT vs Cisplatin-Cetuximab + RT
940 pts, Locally advanced H&N ca
Stage III/IV, T3/T4, M0
SCC of oropharynx, hypopharynx or larynx
.
.
.
End point: PFS, FU: 3.8 years
.
.
No improvement in OS, PFS, LRC or DM
.
.
3 year
OS: 72.9% vs 75.8%
PFS: 61.2% vs 58.9%
LRF: 19.9% vs 25.9%
DM: 13.0% vs 9.7%